Gürlek A, Cobankara V, Bayraktar M
Department of Internal Medicine, Hacettepe University Medical Faculty, Ankara, Turkey.
J Clin Gastroenterol. 1997 Apr;24(3):180-3. doi: 10.1097/00004836-199704000-00013.
Changes in liver biochemical test results have been described in hyperthyroid patients before and after antithyroid therapy. In the present study, we analyzed liver tests at diagnosis and after 6 weeks of treatment with propylthiouracil (PTU) in 43 patients with hyperthyroidism. At diagnosis, 60.5% of the patients had at least one liver abnormality. Elevations of alkaline phosphatase, alanine and aspartate aminotransferase, and gamma-glutamyl transpeptidase levels were observed in 19 (44.2%), 10 (23.3%), six (14%), and six (14%) of the patients, respectively. At the end of the 6-week treatment with PTU, elevations in liver test values, possibly induced by PTU, were found in seven (16.3%) patients. Age, sex, type of goiter (either diffuse or multinodular), and presence or absence of abnormal liver biochemical tests at diagnosis were not significant in determining the possibility of PTU-induced elevations in liver tests. These data suggest that liver test abnormalities are frequently found at the time of diagnosis of hyperthyroidism. However, the presence or absence of these abnormalities does not predict elevations in liver test results, which are possibly induced by PTU during therapy.
甲状腺功能亢进患者在接受抗甲状腺治疗前后肝脏生化检查结果的变化已有相关描述。在本研究中,我们分析了43例甲状腺功能亢进患者在诊断时以及接受丙硫氧嘧啶(PTU)治疗6周后的肝脏检查情况。诊断时,60.5%的患者至少有一项肝脏异常。分别有19例(44.2%)、10例(23.3%)、6例(14%)和6例(14%)患者的碱性磷酸酶、丙氨酸和天冬氨酸转氨酶以及γ-谷氨酰转肽酶水平升高。在接受PTU治疗6周结束时,7例(16.3%)患者出现了可能由PTU引起的肝脏检查值升高。年龄、性别、甲状腺肿类型(弥漫性或多结节性)以及诊断时肝脏生化检查是否异常,在确定PTU引起肝脏检查值升高的可能性方面并无显著意义。这些数据表明,甲状腺功能亢进诊断时经常发现肝脏检查异常。然而,这些异常的存在与否并不能预测治疗期间可能由PTU引起的肝脏检查结果升高。